Results 1 to 10 of about 3,716 (115)
Dermatology and Therapy, 2023 Introduction Hidradenitis suppurativa (HS) is a chronic, immune-mediated skin condition characterized by inflammatory lesions that can cause pain, impaired physical activity, and reduced quality of life.
Alexa B. Kimball +10 more
doaj +2 more sources
Acceptability and tolerability of risankizumab maintenance therapy administered via on-body injector in patients with Crohn’s disease: Results of the ACCEPT-OBI study [PDF]
Therapeutic Advances in GastroenterologyBackground Risankizumab is administered via a new modality, so-called on-body injector (OBI). Objectives To assess the acceptability and the tolerability of OBI-risankizumab therapy, and compare its acceptability with other available modalities in Crohn ...
Anthony Buisson +18 more
doaj +2 more sources
Pharmaceutics, 2023 Risankizumab is a selective, humanized immunoglobulin G1 (IgG1) monoclonal anti-body directed against interleukin (IL)-23 protein. The therapeutic indication of risankizumab is moderate-to-severe plaque psoriasis and psoriatic arthritis.
Fabrizio Calapai +6 more
doaj +3 more sources
Comparative efficacy and safety of IL-23 p19 monoclonal antibodies for plaque psoriasis: a bayesian network meta-analysis of randomized controlled trials [PDF]
Frontiers in ImmunologyObjectiveTo compare the efficacy and safety of IL-23 p19 monoclonal antibodies for moderate-to-severe plaque psoriasis.MethodsPubMed, Embase, Web of Science, and the Cochrane Library were searched from inception to 21 February 2026.
Tong Xin, Shanshan Sun, Yihui Liu
doaj +2 more sources
Efficacy and safety of risankizumab in moderate-to-severe Crohn’s disease: a systematic review and meta-analysis [PDF]
Therapeutic Advances in GastroenterologyBackground: Crohn’s disease (CD) is a chronic inflammatory disorder with limited therapeutic options for treatment-refractory patients. This meta-analysis evaluates the efficacy and safety of risankizumab (IL-23 p19 inhibitor) in moderate-to-severe CD ...
Hafsa Nasim +9 more
doaj +2 more sources
Journal of Immunology Research, 2022 Biological targeted therapy serves as a new alternative treatment for psoriasis due to its minimal side effects. This study is aimed at examining the drug effectiveness and safety of risankizumab and ustekinumab for psoriasis treatment, so as to provide ...
Qianying Yu +7 more
doaj +1 more source
Frontiers in Immunology, 2023 BackgroundRisankizumab, a humanized IgG1 monoclonal antibody that selectively inhibits IL-23, is currently approved for the treatment of moderate-to-severe plaque psoriasis and Crohn’s disease.
Yamin Shu +3 more
doaj +1 more source
Global & Regional Health Technology Assessment, 2021 Purpose: The objective of this analysis was to compare the cost per responder between risankizumab and secukinumab among patients with moderate-to-severe plaque psoriasis in Italy.
Paolo Gisondi +3 more
doaj +1 more source
Efficacy and safety of treatment of moderate and severe psoriasis with the interleukin 23 inhibitor risankizumab [PDF]
Vestnik Dermatologii i Venerologii, 2022 A review of the literature on the use of the genetically engineered biological drug Skyrizi (INN: risankizumab) for the treatment of psoriasis in patients is presented. The problem of high dissatisfaction of patients with the available means (methods) of
Andrey L. Bakulev, Larisa S. Kruglova
doaj +1 more source
Risankizumab in the treatment of psoriasis – literature review
Rheumatology, 2019 Risankizumab is a humanized, monoclonal antibody directed against subunit p19 of interleukin 23 (IL-23). In February 2019, risankizumab was approved for the treatment of moderate to severe psoriasis.
Katarzyna Banaszczyk
doaj +1 more source